Impact of Hydroxychloroquine Treatment on Immunologic Markers in SLE Depends on Ethnicity Laurence S. Magder, PhD – University of Maryland, Baltimore
9:00 AM – 11:00 AM ET
Delineation of a Proinflammatory Cytokine Profile Targeted by Janus Kinase 1/2 Inhibition Using Baricitinib in a Phase 2 Systemic Lupus Erythematosus Trial Thomas Dörner, MD – Charite University Hospitals Berlin
9:00 AM – 11:00 AM ET
Herpes Zoster Events with Anifrolumab in Patients with Active SLE: An Integrated Analysis of Phase 2 and Phase 3 Trials Joan T. Merrill, MD – Oklahoma Medical Research Foundation
9:00 AM – 11:00 AM ET
What Does It Mean to Be a BICLA (BILAG-Based Composite Lupus Assessment) Responder? Post Hoc Analysis of the Phase 3 TULIP-1 and TULIP-2 Trials Richard Furie, MD – Northwell Health
9:00 AM – 11:00 AM ET
Iberdomide Decreases B Cells and Plasmacytoid Dendritic Cells, Increases Regulatory T Cells and IL-2, and Has Enhanced Clinical Efficacy in Active Systemic Lupus Erythematosus Patients with High Aiolos or the IFN Gene Expression Signature Peter E. Lipsky, MD – AMPEL BioSolutions
9:00 AM – 11:00 AM ET
How Much Prednisone Is Enough for Remission Induction in Lupus Nephritis? A Propensity Score Matched Analysis Konstantinos Tselios, MD, PhD – University Health Network
9:00 AM – 11:00 AM ET
Gradual Glucocorticoid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus Konstantinos Tselios, MD, PhD – University Health Network
9:00 AM – 11:00 AM ET
Mortality and Adverse Events of Special Interest in Adult Patients with Systemic Lupus Erythematosus Receiving Intravenous Belimumab: A Post Hoc Descriptive Summary of Serious Psychiatric Events Saira Z. Sheikh, MD – University of North Carolina at Chapel Hill
9:00 AM – 11:00 AM ET
Usage of Corticosteroids and Hospitalisation Duration in Adult Patients with Systemic Lupus Erythematosus (SLE) in Latvia Ilze Vīnkalna – Pauls Stradins Clinical University Hotel
9:00 AM – 11:00 AM ET
Treatment of SLE with or Without Nephritis with the Immunoproteasome Inhibitor KZR-616: Updated Results of the MISSION Study Richard Furie, MD – Northwell Health
9:00 AM – 11:00 AM ET
Time to Renal Insufficiency Based on Prior Hydroxychloroquine Blood Levels Michelle Petri, MD, MPH – Johns Hopkins University School of Medicine
9:00 AM – 11:00 AM ET
Agreement of Hydroxychloroquine Blood Levels Between a University and Commercial Laboratory Michelle Petri, MD, MPH – Johns Hopkins University School of Medicine
9:00 AM – 11:00 AM ET
Leflunomide: A Safe and Effective Alternative in Systemic Lupus Erythematosus Irene Carrión-Barberà, MD – Hospital del Mar
9:00 AM – 11:00 AM ET
Biomarkers of B-cell Depletion and Response in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis Edward Vital, PhD, MBChB, MRCP – University of Leeds
9:00 AM – 11:00 AM ET
PREVAIL 1: A Multiple Ascending Dose Study in Normal Healthy Volunteers of PRV-3279, a Novel Bispecific DART Molecule Targeting CD32B and CD79B on B Cells, with Potential for Treatment of SLE Paul J. Dunford, PhD – Provention Bio
9:00 AM – 11:00 AM ET
Hydroxychloroquine Use Is Associated with Diminished Type I Interferon-related Pathways in Systemic Lupus Erythematosus Patients Samantha Slight-Webb, PhD – Oklahoma Medical Research Foundation
9:00 AM – 11:00 AM ET
Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE Teun van Gelder – Leiden University Medical Centre
9:00 AM – 11:00 AM ET
Residual Treatment Burden, Desired Improvement, and Prioritized Treatment Goals in Systemic Lupus Erythematosus (SLE): Results from the SLE-UPDATE (Understanding Preferences, Disease Activity and Treatment Expectations) Survey in the United States Diane L. Kamen, MD, MSCR – Medical University of South Carolina
9:00 AM – 11:00 AM ET
Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression in Patients with Systemic Lupus Erythematosus Lisa Zhu, MD – UCLA Health
9:00 AM – 11:00 AM ET
Efficacy and Safety of Evobrutinib (M2951) in Adult Patients with Systemic Lupus Erythematosus Who Received Standard of Care Therapy: A Phase II, Randomized, Double-blind, Placebo-controlled Dose Ranging Study Daniel J. Wallace, MD – Attune Health
9:00 AM – 11:00 AM ET
Identifying an SLE Patient Cluster with Greater Treatment Effect: Immune Cell Deconvolution of Gene Expression in Two Atacicept Phase II Studies Joan T. Merrill, MD – Oklahoma Medical Research Foundation
9:00 AM – 11:00 AM ET
Hydroxychloroquine Use Predicts Significantly Higher Patient and Graft Survival in Post-Renal Transplant Lupus Nephritis Patients Shivani Garg, MD, MS – UW Madison
9:00 AM – 11:00 AM ET
Impact of Proteinuria on the Clearance of Monoclonal Antibodies: Potential Clinical Implications Jianmeng Chen – FDA
9:00 AM – 11:00 AM ET
Retinal Toxicity in a Multinational Inception Cohort of Systemic Lupus Patients on Hydroxychloroquine Sasha Bernatsky, MD, PhD – McGill University
9:00 AM – 11:00 AM ET
Hydroxychloroquine Is Associated with Lower Platelet Activity and Improved Vascular Health in Systemic Lupus Erythematosus Elliot Luttrell-Williams – New York University School of Medicine
9:00 AM – 11:00 AM ET
Hydroxychloroquine Dose Reduction and SLE Flares April Jorge, MD – Massachusetts General Hospital
